Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 2, 2011, Pages 169-176

  Niazi, M ^a   Andersson, T ^a   Naucler E ^a   Naesdal J ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Acetylsalicylic acid; Bioequivalence; Esomeprazole; Fixed dose combination

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS ESOMEPRAZOLE; ESOMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CROSSOVER PROCEDURE; DIZZINESS; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADULT; ASPIRIN; CAPSULES; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; OMEPRAZOLE; THERAPEUTIC EQUIVALENCY;

EID: 78751694549     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201400     Document Type: Article

References (23)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
2. PatronoCet al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004; 25: 166-181.
3. Patrono C et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353: 2373-2383.
4. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999; 117: 17-25.
5. Laheij RJ et al. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther. 2001; 15: 1055-1059.
6. Yeomans ND et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005; 22: 795-801.
7. Weil J et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995; 310: 827-830.
8. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001; 1: 1.
9. Kelly JP et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996; 348: 1413-1416.
10. Collet JP et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004; 110: 2361-2367.
11. Ferrari E et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005; 45: 456-459. (Pubitemid 40186800)
12. Maulaz AB et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005; 62: 1217-1220. (Pubitemid 41168347)
13. Biondi-Zoccai GG et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006; 27: 2667-2674.
14. Bhatt DL et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118: 1894-1909.
15. LaiKCet al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002; 346: 2033-2038.
16. Lanas A et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003; 38: 693-700.
17. Yeomans N et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol: 2008; 103: 2465-2473.
18. Iñarrea Pet al. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol. 2000; 35: 242-246.
19. Niazi M et al. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. Int J Clin Pharmacol Ther. 2009; 47: 564-569.
20. Bangalore S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120: 713-719.
21. Pocock SJ. Interim analyses for randomized clinical trials: the group sequential approach. Biometrics. 1982; 38: 153-162.
22. Nefesoglu FZ et al. Interaction of omeprazole with enteric-coated salicylate tablets. Int J Clin Pharmacol Ther. 1998; 36: 549-553.
23. FDA Guidance. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). http://www.fda.gov/cder/guidance/index.htm. 2003.